Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Raw Materials (2016 - 2018)

Historic Raw Materials for Anika Therapeutics (ANIK) over the last 8 years, with Q3 2018 value amounting to $13.2 million.

  • Anika Therapeutics' Raw Materials rose 6831.07% to $13.2 million in Q3 2018 from the same period last year, while for Sep 2018 it was $13.2 million, marking a year-over-year increase of 6831.07%. This contributed to the annual value of $11.3 million for FY2017, which is 9197.82% up from last year.
  • Anika Therapeutics' Raw Materials amounted to $13.2 million in Q3 2018, which was up 6831.07% from $12.6 million recorded in Q2 2018.
  • In the past 5 years, Anika Therapeutics' Raw Materials registered a high of $13.2 million during Q3 2018, and its lowest value of $4.9 million during Q3 2015.
  • Its 5-year average for Raw Materials is $7.4 million, with a median of $6.3 million in 2017.
  • Its Raw Materials has fluctuated over the past 5 years, first plummeted by 2895.64% in 2015, then soared by 10012.72% in 2018.
  • Anika Therapeutics' Raw Materials (Quarter) stood at $6.2 million in 2014, then decreased by 6.2% to $5.8 million in 2015, then rose by 1.8% to $5.9 million in 2016, then skyrocketed by 91.98% to $11.3 million in 2017, then grew by 17.22% to $13.2 million in 2018.
  • Its Raw Materials stands at $13.2 million for Q3 2018, versus $12.6 million for Q2 2018 and $10.1 million for Q1 2018.